DexCom Operating Income from 2010 to 2026
| DXCM Stock | USD 73.26 0.18 0.25% |
Operating Income | First Reported 2003-12-31 | Previous Quarter 242.5 M | Current Value 323 M | Quarterly Volatility 76.1 M |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.5 M, Other Operating Expenses of 3.9 B or Operating Income of 957.4 M, as well as many indicators such as Price To Sales Ratio of 5.28, Dividend Yield of 0.0 or PTB Ratio of 9.99. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Operating Income | Build AI portfolio with DexCom Stock |
Evaluating DexCom's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.
Latest DexCom's Operating Income Growth Pattern
Below is the plot of the Operating Income of DexCom Inc over the last few years. Operating Income is the amount of profit realized from DexCom Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of DexCom Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. DexCom's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
DexCom Operating Income Regression Statistics
| Arithmetic Mean | 215,349,000 | |
| Coefficient Of Variation | 166.65 | |
| Mean Deviation | 295,993,765 | |
| Median | (4,014,000) | |
| Standard Deviation | 358,883,949 | |
| Sample Variance | 128797.7T | |
| Range | 1.1B | |
| R-Value | 0.86 | |
| Mean Square Error | 35374.1T | |
| R-Squared | 0.74 | |
| Slope | 61,240,277 | |
| Total Sum of Squares | 2060763T |
DexCom Operating Income History
Other Fundumenentals of DexCom Inc
DexCom Operating Income component correlations
Click cells to compare fundamentals
About DexCom Financial Statements
DexCom investors utilize fundamental indicators, such as Operating Income, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 911.8 M | 957.4 M | |
| Non Operating Income Net Other | 20.7 M | 21.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of DexCom Correlation against competitors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.78 | Earnings Share 2.09 | Revenue Per Share | Quarterly Revenue Growth 0.131 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.